Thoracic Tumors
Meta-analysis of the incidence of radiation pneumonitis between European, American and Asian populations
Wei Jia, Zhang Zhen, Yu Jiaqi, Jia Huijun, Tian Jia, Meng Chunliu, Ren Kai, Zhao Lujun
Published 2021-06-15
Cite as Chin J Radiat Oncol, 2021, 30(6): 556-562. DOI: 10.3760/cma.j.cn113030-20201114-00554
Abstract
ObjectiveTo compare the incidence of radiation pneumonitis (RP) between lung cancer patients from the European, American and Asian regions.
MethodsThe studies related to lung cancer and RP were searched from PubMed, Embase, and Cochrane library. According to the different places where the studies were conducted, the searched studies were divided into two types: Asian studies and European, American and Australian studies. The incidence of RP between two regions was summarized. Studies related to dosimetry parameters were searched from PubMed database.
ResultsA total of 3, 190 patients from 14studies were included. Meta-analysis results showed that the incidence of ≥ grade 3 RP was similar in patients from Asia and Europe, America and Australia (4.9% vs. 4.6%, P=0.895), whereas the incidence of grade 5 RP in Asia was significantly higher than that in Europe, America and Australia (1.5% vs. 0.2%, P=0.002). Moreover, the lung irradiation dose received by the patients in the Asian group was relatively low. Lung V20Gy dose limitation standard was reported in 21studies. Further analysis found no statistical significance in lung V20Gy dose limitation standard between two regions (P=0.440), and the standard in Asian studies is likely to be even stricter.
ConclusionsThe incidence of RP after chemoradiotherapy in lung cancer patients in Asia is relatively higher compared with those in Europe, America and Australia. The differences in dose limitation standard should be noted when the thoracic radiation regimen based solely on the data from foreign studies is applied to the patients in Asia.
Key words:
Lung neoplasm/radiotherapy; Radiation pneumonitis; Meta-analysis
Contributor Information
Wei Jia
Department of Radiation Oncology, Cancer Hospital of Tianjin Medical University, National Cancer Clinical Medical Research Center, Tianjin "Tumor Prevention and Control" Key Laboratory, Tianjin Malignant Tumor Clinical Medicine Research Center, Tianjin 300060, China
Zhang Zhen
Department of Radiation Oncology, Cancer Hospital of Tianjin Medical University, National Cancer Clinical Medical Research Center, Tianjin "Tumor Prevention and Control" Key Laboratory, Tianjin Malignant Tumor Clinical Medicine Research Center, Tianjin 300060, China
Yu Jiaqi
Department of Radiation Oncology, Cancer Hospital of Tianjin Medical University, National Cancer Clinical Medical Research Center, Tianjin "Tumor Prevention and Control" Key Laboratory, Tianjin Malignant Tumor Clinical Medicine Research Center, Tianjin 300060, China
Jia Huijun
Department of Radiation Oncology, Cancer Hospital of Tianjin Medical University, National Cancer Clinical Medical Research Center, Tianjin "Tumor Prevention and Control" Key Laboratory, Tianjin Malignant Tumor Clinical Medicine Research Center, Tianjin 300060, China
Tian Jia
Department of Radiation Oncology, Cancer Hospital of Tianjin Medical University, National Cancer Clinical Medical Research Center, Tianjin "Tumor Prevention and Control" Key Laboratory, Tianjin Malignant Tumor Clinical Medicine Research Center, Tianjin 300060, China
Meng Chunliu
Department of Radiation Oncology, Cancer Hospital of Tianjin Medical University, National Cancer Clinical Medical Research Center, Tianjin "Tumor Prevention and Control" Key Laboratory, Tianjin Malignant Tumor Clinical Medicine Research Center, Tianjin 300060, China
Ren Kai
Department of Radiation Oncology, Cancer Hospital of Tianjin Medical University, National Cancer Clinical Medical Research Center, Tianjin "Tumor Prevention and Control" Key Laboratory, Tianjin Malignant Tumor Clinical Medicine Research Center, Tianjin 300060, China
Zhao Lujun
Department of Radiation Oncology, Cancer Hospital of Tianjin Medical University, National Cancer Clinical Medical Research Center, Tianjin "Tumor Prevention and Control" Key Laboratory, Tianjin Malignant Tumor Clinical Medicine Research Center, Tianjin 300060, China